EBV-related nasopharyngeal carcinoma (NPC) significantly affects Asian Americans and Native Hawaiians/other Pacific Islanders in the U.S. who lack screening access, and early detection has proven effective in Asian trials.
Analysis of NPC incidence data highlighted that 10.7% of the U.S. population accounts for 42.7% of NPC cases, with anti-BNLF2b screening being the most effective method, potentially reducing mortality significantly.
The recommended target group for NPC screening in the U.S. consists of certain ethnic men and women aged 35 to 65, indicating that a one-time screening approach could be both effective and economically feasible.